BR9915918A - Combinação de carnitinas e resveratrol para prevenção ou tratamento de distúrbios cerebrais ou de envelhecimento - Google Patents

Combinação de carnitinas e resveratrol para prevenção ou tratamento de distúrbios cerebrais ou de envelhecimento

Info

Publication number
BR9915918A
BR9915918A BR9915918-0A BR9915918A BR9915918A BR 9915918 A BR9915918 A BR 9915918A BR 9915918 A BR9915918 A BR 9915918A BR 9915918 A BR9915918 A BR 9915918A
Authority
BR
Brazil
Prior art keywords
resveratrol
carnitines
combination
aging
prevent
Prior art date
Application number
BR9915918-0A
Other languages
English (en)
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of BR9915918A publication Critical patent/BR9915918A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>"COMBINAçãO DE CARNITINAS E RESVERATROL PARA PREVENçãO OU TRATAMENTO DE DISTúRBIOS CEREBRAIS OU DE ENVELHECIMENTO"<D>. Um produto farmacêutico que compreende (A) L-carnitina ou uma alcanoil L-carnitina embaladas em mistura ou separadamente (por exemplo, acetil L-carnitina ou proprionil L-carnitina) e (B) um trihidróxi ou tetrahidroxiestilbeno (por exemplo, resveratrol) é útil para a prevenção e tratamento de formas patológicas devido a distúrbios neuroniais ou cerebrais.
BR9915918-0A 1998-10-09 1999-10-06 Combinação de carnitinas e resveratrol para prevenção ou tratamento de distúrbios cerebrais ou de envelhecimento BR9915918A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1998RM000636A IT1302365B1 (it) 1998-10-09 1998-10-09 Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali
PCT/IT1999/000311 WO2000021526A1 (en) 1998-10-09 1999-10-06 Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders

Publications (1)

Publication Number Publication Date
BR9915918A true BR9915918A (pt) 2001-08-21

Family

ID=11406160

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915918-0A BR9915918A (pt) 1998-10-09 1999-10-06 Combinação de carnitinas e resveratrol para prevenção ou tratamento de distúrbios cerebrais ou de envelhecimento

Country Status (27)

Country Link
US (1) US6515020B1 (pt)
EP (1) EP1117394B1 (pt)
JP (1) JP4166951B2 (pt)
KR (1) KR20010079981A (pt)
CN (1) CN1323205A (pt)
AR (1) AR020762A1 (pt)
AT (1) ATE249823T1 (pt)
AU (1) AU767492B2 (pt)
BR (1) BR9915918A (pt)
CA (1) CA2344893C (pt)
CZ (1) CZ2001920A3 (pt)
DE (1) DE69911441T2 (pt)
DK (1) DK1117394T3 (pt)
EE (1) EE200100205A (pt)
ES (1) ES2207287T3 (pt)
HK (1) HK1040935A1 (pt)
HU (1) HU229364B1 (pt)
IL (1) IL142046A0 (pt)
IS (1) IS5896A (pt)
IT (1) IT1302365B1 (pt)
NO (1) NO20011693D0 (pt)
PL (1) PL197342B1 (pt)
PT (1) PT1117394E (pt)
SK (1) SK3782001A3 (pt)
TN (1) TNSN99186A1 (pt)
TR (1) TR200100947T2 (pt)
WO (1) WO2000021526A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002047193A (ja) * 2000-07-31 2002-02-12 Sunstar Inc アレルギー性皮膚炎予防または治療用組成物
AU2002236438A1 (en) * 2000-11-08 2002-05-21 Massachusetts Institute Of Technology Compositions and methods for treatment of mild cognitive impairment
BRPI0106382B1 (pt) * 2001-03-13 2017-07-11 Universidade Do Estado Do Rio De Janeiro - Uerj Process for obtaining decocts from vitis labrusca and vitis vinifera casts, process for obtaining the hydro-alcoholic extract, process for obtaining the hydro-alcoholic extract-ethyl acetate and pharmaceutical compositions
ATE342044T1 (de) * 2001-08-18 2006-11-15 Cognis Ip Man Gmbh Wirkstoffmischungen
US20070218152A1 (en) * 2002-03-12 2007-09-20 Roberto Moura Process for obtention of decoctions of Vitis labrusca and Vitis vinifera skins
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
KR100574392B1 (ko) * 2003-02-07 2006-05-02 재단법인서울대학교산학협력재단 신경보호활성을 갖는 신규 페닐환 유도체 및 이를함유하는 약학 조성물
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
WO2005002672A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cells/organism lifespan/stress response
KR100543056B1 (ko) * 2003-11-07 2006-01-20 (주)네추럴에프앤피 신경세포 보호 활성이 있는 포도씨 추출물을 포함하는뇌질환 예방 및 치료용 조성물
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
JP2007527418A (ja) 2003-12-29 2007-09-27 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 肥満及びインシュリン耐性障害を治療又は防止するための組成物
ES2245609B1 (es) * 2004-06-18 2007-08-16 Universidad De Barcelona Nuevo agente terapeutico para el tratamiento de la infertilidad y/o subfertilidad masculina en mamiferos.
WO2006004722A2 (en) * 2004-06-30 2006-01-12 Biomol Research Laboratories, Inc. Compositions and methods for selectively activating human sirtuins
US20060121137A1 (en) * 2004-12-07 2006-06-08 Hartle Diane K Muscadine grape pomace in the treatment of intestinal inflammation
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
EP1993522A2 (en) 2005-10-26 2008-11-26 Kao Corporation Resveratrol and/or grape leaf extract as i.a. endurance improver, anti-aging agent, muscle strength improver
FR2898493B1 (fr) * 2006-03-16 2008-08-08 Af Consulting Compositions cosmetiques, pharmaceutiques, alimentaires et veterinaires dont l'action d'activation de genes de type sirtuin permet de retarder le vieillissement des mammiferes et ses effets nefastes
US20120016037A1 (en) * 2006-07-24 2012-01-19 Frank Toppo Method for prevention and treatment of Alzheimers
CA2676609A1 (en) * 2007-01-26 2008-07-31 Washington University Methods and compositions for treating neuropathies
AT506014A1 (de) * 2007-10-24 2009-05-15 Karl Mag Dr Zehethofer Functional drink
SG10201503032UA (en) * 2010-06-16 2015-06-29 Sigma Tau Ind Farmaceuti Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue
KR101327936B1 (ko) * 2011-07-06 2013-11-13 한국식품연구원 옥시레스베라트롤 이민 유도체를 유효성분으로 함유하는 뇌신경보호 효과를 가지는 조성물
CN102919943A (zh) * 2012-10-26 2013-02-13 郑全辉 保健饮品-葡藤素
CN103877170B (zh) * 2012-12-19 2015-11-04 中国医学科学院药用植物研究所 一种虎杖的乙酸乙酯提取物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1276225B1 (it) 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
IT1283967B1 (it) * 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi
CA2280093A1 (en) * 1997-02-04 1998-08-06 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
IT1291113B1 (it) 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
CH692837A5 (it) * 1997-07-02 2002-11-29 Lisapharma Spa Composizione farmaceutica per uso alimentare, dietetico o medicinale adatta a migliorare l'assorbimento orale dei polifenoli e particolarmente del resveratrolo presenti nell'uva e nei suoi p
US5904924A (en) * 1997-11-04 1999-05-18 Oncologics, Inc. Green nutritional powder composition
WO1999059561A2 (en) * 1998-05-18 1999-11-25 Hensley, Kenneth, L. Resveratrol inhibition of myeloperoxidase

Also Published As

Publication number Publication date
IT1302365B1 (it) 2000-09-05
TNSN99186A1 (fr) 2005-11-10
KR20010079981A (ko) 2001-08-22
CN1323205A (zh) 2001-11-21
PL197342B1 (pl) 2008-03-31
ITRM980636A1 (it) 2000-04-10
NO20011693L (no) 2001-04-04
IL142046A0 (en) 2002-03-10
AU6121399A (en) 2000-05-01
PL347209A1 (en) 2002-03-25
JP4166951B2 (ja) 2008-10-15
DK1117394T3 (da) 2004-01-26
CA2344893A1 (en) 2000-04-20
PT1117394E (pt) 2004-02-27
TR200100947T2 (tr) 2001-07-23
HUP0104021A2 (hu) 2002-02-28
DE69911441D1 (de) 2003-10-23
CA2344893C (en) 2008-07-29
SK3782001A3 (en) 2001-10-08
US6515020B1 (en) 2003-02-04
JP2002527389A (ja) 2002-08-27
WO2000021526A1 (en) 2000-04-20
ATE249823T1 (de) 2003-10-15
ES2207287T3 (es) 2004-05-16
AR020762A1 (es) 2002-05-29
HU229364B1 (en) 2013-11-28
AU767492B2 (en) 2003-11-13
DE69911441T2 (de) 2004-07-01
CZ2001920A3 (cs) 2001-08-15
EE200100205A (et) 2002-06-17
IS5896A (is) 2001-03-16
EP1117394A1 (en) 2001-07-25
NO20011693D0 (no) 2001-04-04
EP1117394B1 (en) 2003-09-17
HK1040935A1 (zh) 2002-06-28
HUP0104021A3 (en) 2003-12-29

Similar Documents

Publication Publication Date Title
BR9915918A (pt) Combinação de carnitinas e resveratrol para prevenção ou tratamento de distúrbios cerebrais ou de envelhecimento
BR9913288A (pt) Composição antioxidante compreendendo acetil l-carnitina e ácido alfa-lipóico
BR9911440A (pt) Composição para a prevenção e/ou tratamento de osteoporose e alterações devido à sìndrome de menopausa
BR9908488A (pt) Composição farmacêutica de topiramato
BR9709915A (pt) Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto
BR0112799A (pt) Composição farmacêutica, processo para preparação e utilização da mesma, conjunto e processo para tratamento de obesidade, utilização de um inibidor de lìpase e de um sequestrante de ácido de bìlis e processo de tratamento ou prevencão de efeitos colaterais gastrointestinais
BR9916197A (pt) Método para o tratamento de isquemia cerebral e uso de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral
BR9808348A (pt) Alimento medicinal para diabéticos
ATE305301T1 (de) Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid
BR0207950A (pt) Confeito compósito flexìvel congelado compreendendo um gel e processo para sua preparação
BR9507010A (pt) Processos para aumentar o nível de HBF em um indivíduo e para tratar prevenir ou melhorar b-globina ou outros distúrbios relacionados com HBF
BR9806184A (pt) Inibidores de butirilcolinesterase altamente seletivos para o tratamento e o diagnóstico da doença de alzheimer e demências
BR9814711A (pt) Composições e processos para aumentar a concentração e/ou motilidade de espermatozóides em seres humanos
BR9914735A (pt) Processo para tratamento de sépsia
BR0114344A (pt) Retinóides para o tratamento de enfisema
BR9912703A (pt) Composição antioxidante, antiprolìfera, compreendendo uma carnitina e um carotenóide
BR0210650A (pt) Tablete, e, uso do mesmo
AU5636300A (en) Use of creatine or creatine analogs for the prevention and treatment of transmissible spongiform encephalopathies
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
BR9810703A (pt) Composição farmacêutica, e, processos para a preparação da mesma, e para tratar um distúrbio de agregação de plaqueta
BR9707210A (pt) Preparado de combinação farmacêutico a partir de análogos de ihrh e antiestrogênios para o tratamento de distúrbios ginecológicos
BR0012058A (pt) Combinação sinérgica: gabapentina e pregabalina
BRPI0417796A (pt) preparado efervescente de uma substáncia básica de efeito medicinal
BR0210007A (pt) Uso de inibidores de il-18 para tratamento ou prevenção de lesões do sistema nervoso central
BR9808866A (pt) Moléculas retinóicas relacionadas à inibição da superprodução de endotelina-1 em doenças

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/205 (2006.01), A23L 33/10 (2016.0